[{"id":"47419cad-33d1-4efc-a6a0-f1c6cbbcc254","acronym":"","url":"https://clinicaltrials.gov/study/NCT02518555","created_at":"2021-01-18T12:10:14.260Z","updated_at":"2024-07-02T16:35:02.891Z","phase":"Phase 2","brief_title":"Ibrutinib as an Immune Modulating Agent for Patients With Asymptomatic, High-risk CLL/SLL Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","source_id_and_acronym":"NCT02518555","lead_sponsor":"Jennifer Woyach","biomarkers":" TP53","pipe":" | ","alterations":" Chr del(11q) • Chr del(17)(p13.1)","tags":["TP53"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr del(11q) • Chr del(17)(p13.1)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imbruvica (ibrutinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 42","initiation":"Initiation: 01/12/2016","start_date":" 01/12/2016","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-05-17"}]